iShares Genomics Immunology and Healthcare ETF (XDNA)

Overview

The company operates on a passive management investment strategy, aiming to mirror the total return performance of a specialized index. This particular index is structured around a rules-based methodology, focusing exclusively on companies involved in various aspects of DNA Modification Technology. By dedicating at least 80% of its net assets to investments in these DNA Modification Technology Companies, the fund distinctly focuses on a niche yet rapidly evolving sector. Given its targeted investment approach, the fund is categorized as non-diversified, concentrating its assets in what is perceived as a high-potential area of the biotech industry.

Products and Services

• Passive Management Investment Approach:

  Utilizing a passive management strategy, the company aims to replicate the performance of the index it tracks, without actively buying and selling assets to beat the market. This approach aligns with investors seeking exposure to the DNA Modification Technology sector without the risks and costs associated with active fund management.

• Rules-based DNA Modification Technology Index:

  The core of the fund's investment strategy lies in its adherence to a rules-based index. This index comprises companies that are actively involved in the DNA Modification Technology space, including but not limited to creation, development, production, operation, and distribution. The focus on a specific segment of the biotech industry allows for targeted investment in a field with significant growth potential.

• Investment in DNA Modification Technology Companies:

  In line with its strategy, the fund invests at least 80% of its net assets directly into companies that are pioneers in DNA modification technology. This includes entities that are engaged in the servicing, licensing, leasing, or franchising related to this technology, offering investors a focused yet potentially lucrative exposure to the biotech sector.

• Non-diversified Fund Structure:

  The fund’s classification as non-diversified means it may invest a larger portion of its assets in a smaller number of companies. While this can lead to higher volatility and risk in comparison to diversified funds, it also presents the opportunity for significant returns by concentrating on the promising DNA Technology sector.